( SAN DIEGO--(BUSINESS WIRE)--Jun 6 2007...)Metabasis Therapeutics Presents Results of Preclinical Studies for,MB07811, Its Novel Product Candidate for the Treatment of,Hyperlipidemia, at the Endocrine Society's Annual Meeting,Health

SAN DIEGO--(BUSINESS WIRE)--Jun 6, 2007 - Metabasis Therapeutics, Inc. (Nasdaq:MBRX), a biopharmaceutical company focused on the discovery, development and commercialization of novel drugs for the treatment of metabolic and liver diseases by applying unique capabilities for targeting the liver and liver pathways, announced today that two posters were presented at the Endocrine Society's 89th Annual Meeting in Toronto, Canada.

Both posters provide data on MB07811, the Company's liver-targeted, beta-subtype-selective thyroid hormone receptor (TR beta) agonist product candidate for the treatment of hyperlipidemia. The first poster provides data that show that MB07811 significantly reduced cholesterol and triglyceride levels in certain animal models with an improved therapeutic index as compared to the natural ligand, T3, or a prototype non-liver-targeted TR beta-selective agonist (KB-141). Oral administration of MB07811 to rats led to liver-selective tissue distribution with minimal effects on gene expression in extra-hepatic tissues. The studies in rats and mice showed an improved safety profile, including no cardiac effects and reduced effects on the thyroid hormone axis compared to KB-141.

The second poster provides data showing that oral administration of MB07811 resulted in a robust lowering of plasma cholesterol in a variety of animal models. Sustained efficacy was apparent with continued daily dosing for a duration of 4 to 9 weeks of treatment. Also noted, but not presented in the poster, were demonstrations of activity in a monkey model, and additive activity to statins in the monkey and rabbit models.

Thyroid hormone receptor (TR) agonists represent a novel and potentially important approach for reducing LDL-cholesterol (known as the "bad" cholesterol) and total cholesterol, liver and serum triglycerides, and lipoprotein (a) (Lp(a)). However, use of this approach has been hampered by dose-li
'"/>

Page: 1 2 3 4
Related medicine technology :

1. Metabasis to Present at C.E. Unterberg, Towbin Emerging Growth Conference and Attend Pacific Growth Equities Conference
2. Metabasis Therapeutics to Present Poster at American Association for Cancer Research
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
5. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
6. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
7. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
8. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer